Vildagliptin
Eucreas, Galvus, Icandra, Jalra, Vildagliptin / Metformin, Xiliarx, Zomarist (vildagliptin) is a small molecule pharmaceutical. Vildagliptin was first approved as Galvus on 2007-09-25. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| anorectal | OTC monograph final | 2017-12-29 |
| avobenzone, homosalate, octisalate, octocrylene, oxybenzone | OTC monograph not final | 2019-06-26 |
| chocolate laxative | C200263 | 2024-12-23 |
| daytime nighttime childrens multi-symptom cold | C200263 | 2024-11-26 |
| discount drug mart eye drops advanced relief | OTC monograph final | 2023-03-20 |
| each relief | OTC monograph not final | 2017-01-20 |
| ear wax removal drops | C200263 | 2023-12-04 |
| earwax removal drops | OTC monograph final | 2017-12-29 |
| eqaute-sunscreen sport spf 100 | OTC monograph not final | 2019-02-13 |
| equagesic | 2008-01-15 |
Show 371 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD08: Metformin and vildagliptin
— A10BH: Dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering
— A10BH02: Vildagliptin
HCPCS
No data
Clinical
Clinical Trials
210 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 6 | 8 | 76 | 56 | 22 | 163 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 3 | 11 | 62 | 25 | 8 | 105 |
| Hypoglycemia | D007003 | — | E16.2 | — | — | — | 6 | — | 6 |
| Renal insufficiency | D051437 | — | N19 | 1 | 1 | 4 | 1 | — | 6 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | 2 | 3 | — | 5 |
| Hyperglycemia | D006943 | — | R73.9 | — | — | 3 | 2 | — | 5 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 2 | 2 | 4 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 3 | 1 | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | 1 | 2 | — | 4 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 2 | 1 | 3 |
Show 27 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | 1 | — | 1 | 7 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | 2 | — | — | 3 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | 2 | — | — | 2 |
| Retinal neovascularization | D015861 | — | H35.05 | — | 1 | 1 | — | — | 1 |
| Pathologic neovascularization | D009389 | — | — | — | 1 | 1 | — | — | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | 1 | — | — | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | 1 | 1 | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 1 | — | — | — | 1 |
| Dyslipidemias | D050171 | — | — | — | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Kidney transplantation | D016030 | — | — | — | 1 | — | — | — | 1 |
| Gestational diabetes | D016640 | — | O24.4 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 2 | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 2 | 2 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 2 | 2 |
| Therapeutic equivalency | D013810 | — | — | — | — | — | — | 2 | 2 |
| Psychological distress | D000079225 | — | — | — | — | — | — | 2 | 2 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 1 | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 1 | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 1 | 1 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 1 | 1 |
| Truncal vagotomy | D015167 | — | — | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vildagliptin |
| INN | vildagliptin |
| Description | Vildagliptin is an amino acid amide. |
| Classification | Small molecule |
| Drug class | dipeptidyl aminopeptidase-IV inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2 |
Identifiers
| PDB | — |
| CAS-ID | 274901-16-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL142703 |
| ChEBI ID | — |
| PubChem CID | 6918537 |
| DrugBank | DB04876 |
| UNII ID | I6B4B2U96P (ChemIDplus, GSRS) |
Target
Agency Approved
DPP4
DPP4
Organism
Homo sapiens
Gene name
DPP4
Gene synonyms
ADCP2, CD26
NCBI Gene ID
Protein name
dipeptidyl peptidase 4
Protein synonyms
ADABP, ADCP-2, Adenosine deaminase complexing protein 2, CD26, Dipeptidyl peptidase IV, dipeptidylpeptidase 4, dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2), DPP IV, Gly-Pro naphthylamidase, Post-proline dipeptidyl aminopeptidase IV, T-cell activation antigen CD26, TP103, Xaa-Pro-dipeptidylaminopeptidase
Uniprot ID
Mouse ortholog
Dpp4 (13482)
dipeptidyl peptidase 4 (Q3U514)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Galvus – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,812 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,845 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use